Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009;14(2):293-7.
doi: 10.1177/135965350901400211.

Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda

Steven J Reynolds  1 , Cissy Kityo, Frank Mbamanya, Robin Dewar, Francis Ssali, Thomas C Quinn, Peter Mugyenyi, Mark Dybul
Affiliations

Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda

Steven J Reynolds et al. Antivir Ther. 2009.

Abstract

Background: This study aimed to determine the extent of viral resistance over time among non-clade B HIV type-1-infected patients in Uganda who were maintained on first-line highly active antiretroviral therapy (HAART) following virological failure.

Methods: Genotyping was performed on 16 patients with virological failure who were enrolled in an open-label randomized clinical trial of short-cycle treatment interruption.

Results: All patients receiving efavirenz-containing HAART had > or =1 efavirenz resistance mutation develop during follow-up. The majority (13/15, 86%) developed lamivudine resistance during follow-up, but no thymidine analogue mutations (TAMs) developed during a median duration of virological failure of 325.5 days.

Conclusions: Genotype resistance to both efavirenz and lamivudine developed early during the course of treatment after virological failure. TAMs did not emerge early despite moderate exposure time to thymidine analogues during virological failure.

PubMed Disclaimer

References

    1. Galarraga O, O'Brien ME, Gutierrez JP, Renaud-Thery F, Nguimfack BD, Beusenberg M, Waldman K, Soni A, Bertozzi SM, Greener R. Forecast of demand for antiretroviral drugs in low and middle-income countries: 2007-2008. AIDS. 2007 July;21(Suppl 4):S97–103. - PubMed
    1. Renaud-Thery F, Nguimfack BD, Vitoria M, Lee E, Graaff P, Samb B, Perriens J. Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens. AIDS. 2007 July;21(Suppl 4):S89–S955. - PubMed
    1. Calmy A, Ford N, Hirschel B, Reynolds SJ, Lynen L, Goemaere E, Garcia dl V, Perrin L, Rodriguez W. HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis. 2007 January 1;44(1):128–34. - PubMed
    1. Ugandan Ministry of Health 2008.
    1. Cozzi-Lepri A, Phillips AN, Ruiz L, Clotet B, Loveday C, Kjaer J, Mens H, Clumeck N, Viksna L, Antunes F, Machala L, Lundgren JD. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS. 2007 March 30;21(6):721–32. - PubMed

Publication types